Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Increase in Short Interest

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 54,264 shares, an increase of 112.1% from the December 15th total of 25,588 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 468,130 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 468,130 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.5% of the company’s stock are sold short.

Wall Street Analyst Weigh In

RADX has been the topic of a number of recent analyst reports. B. Riley reissued a “buy” rating and set a $16.00 target price (up from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $15.33.

Institutional Trading of Radiopharm Theranostics

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. boosted its position in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,000 shares of the company’s stock after acquiring an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent reporting period.

Radiopharm Theranostics Stock Up 0.6%

Shares of NASDAQ:RADX traded up $0.03 during midday trading on Wednesday, reaching $5.20. The company’s stock had a trading volume of 43,454 shares, compared to its average volume of 148,299. Radiopharm Theranostics has a fifty-two week low of $3.50 and a fifty-two week high of $16.25. The firm has a 50 day moving average price of $4.97 and a two-hundred day moving average price of $5.29.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.